Biodol Therapeutics
French tech company | Builders Republic
About
Clinical-stage biotech developing first-in-class small-molecule FLT3 extracellular antagonists to treat chronic neuropathic pain and migraine — lead candidate BDT272 completed Phase 1, with a worldwide license agreement signed with Japanese pharma KYORIN.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2015
- City
- MONTARNAUD
- Region
- Occitanie
- Tracked rounds
- 1
- Amount raised
- 4.5 M€ raised since 2020
Funding rounds
- Series A — 2020
Investors
- bpifrance
- V-Bio Ventures